The National Cancer Institute ALMANAC: A comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity

Susan L. Holbeck, Richard Camalier, James A. Crowell, Jeevan Prasaad Govindharajulu, Melinda Hollingshead, Lawrence W. Anderson, Eric Polley, Larry Rubinstein, Apurva Srivastava, Deborah Wilsker, Jerry M. Collins, James H. Doroshow

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

To date, over 100 small-molecule oncology drugs have been approved by the FDA. Because of the inherent heterogeneity of tumors, these small molecules are often administered in combination to prevent emergence of resistant cell subpopulations. Therefore, new combination strategies to overcome drug resistance in patients with advanced cancer are needed. In this study, we performed a systematic evaluation of the therapeutic activity of over 5,000 pairs of FDA-approved cancer drugs against a panel of 60 well-characterized human tumor cell lines (NCI-60) to uncover combinations with greater than additive growth-inhibitory activity. Screening results were compiled into a database, termed the NCI-ALMANAC (A Large Matrix of Anti-Neoplastic Agent Combinations), publicly available at https://dtp.cancer.gov/ncial manac. Subsequent in vivo experiments in mouse xenograft models of human cancer confirmed combinations with greater than single-agent efficacy. Concomitant detection of mechanistic biomarkers for these combinations in vivo supported the initiation of two phase I clinical trials at the NCI to evaluate clofarabine with bortezomib and nilotinib with paclitaxel in patients with advanced cancer. Consequently, the hypothesis-generating NCI-ALMANAC web-based resource has demonstrated value in identifying promising combinations of approved drugs with potent anticancer activity for further mechanistic study and translation to clinical trials.

Original languageEnglish (US)
Pages (from-to)3564-3576
Number of pages13
JournalCancer Research
Volume77
Issue number13
DOIs
StatePublished - Jul 1 2017
Externally publishedYes

Fingerprint

National Cancer Institute (U.S.)
Pharmaceutical Preparations
Neoplasms
Therapeutics
Clinical Trials, Phase I
Drug Combinations
Paclitaxel
Tumor Cell Line
Drug Resistance
Heterografts
Biomarkers
Clinical Trials
Databases
Growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Holbeck, S. L., Camalier, R., Crowell, J. A., Govindharajulu, J. P., Hollingshead, M., Anderson, L. W., ... Doroshow, J. H. (2017). The National Cancer Institute ALMANAC: A comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity. Cancer Research, 77(13), 3564-3576. https://doi.org/10.1158/0008-5472.CAN-17-0489

The National Cancer Institute ALMANAC : A comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity. / Holbeck, Susan L.; Camalier, Richard; Crowell, James A.; Govindharajulu, Jeevan Prasaad; Hollingshead, Melinda; Anderson, Lawrence W.; Polley, Eric; Rubinstein, Larry; Srivastava, Apurva; Wilsker, Deborah; Collins, Jerry M.; Doroshow, James H.

In: Cancer Research, Vol. 77, No. 13, 01.07.2017, p. 3564-3576.

Research output: Contribution to journalArticle

Holbeck, SL, Camalier, R, Crowell, JA, Govindharajulu, JP, Hollingshead, M, Anderson, LW, Polley, E, Rubinstein, L, Srivastava, A, Wilsker, D, Collins, JM & Doroshow, JH 2017, 'The National Cancer Institute ALMANAC: A comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity', Cancer Research, vol. 77, no. 13, pp. 3564-3576. https://doi.org/10.1158/0008-5472.CAN-17-0489
Holbeck, Susan L. ; Camalier, Richard ; Crowell, James A. ; Govindharajulu, Jeevan Prasaad ; Hollingshead, Melinda ; Anderson, Lawrence W. ; Polley, Eric ; Rubinstein, Larry ; Srivastava, Apurva ; Wilsker, Deborah ; Collins, Jerry M. ; Doroshow, James H. / The National Cancer Institute ALMANAC : A comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity. In: Cancer Research. 2017 ; Vol. 77, No. 13. pp. 3564-3576.
@article{1d210966c528459b9d6cf2f0f5d6d8a7,
title = "The National Cancer Institute ALMANAC: A comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity",
abstract = "To date, over 100 small-molecule oncology drugs have been approved by the FDA. Because of the inherent heterogeneity of tumors, these small molecules are often administered in combination to prevent emergence of resistant cell subpopulations. Therefore, new combination strategies to overcome drug resistance in patients with advanced cancer are needed. In this study, we performed a systematic evaluation of the therapeutic activity of over 5,000 pairs of FDA-approved cancer drugs against a panel of 60 well-characterized human tumor cell lines (NCI-60) to uncover combinations with greater than additive growth-inhibitory activity. Screening results were compiled into a database, termed the NCI-ALMANAC (A Large Matrix of Anti-Neoplastic Agent Combinations), publicly available at https://dtp.cancer.gov/ncial manac. Subsequent in vivo experiments in mouse xenograft models of human cancer confirmed combinations with greater than single-agent efficacy. Concomitant detection of mechanistic biomarkers for these combinations in vivo supported the initiation of two phase I clinical trials at the NCI to evaluate clofarabine with bortezomib and nilotinib with paclitaxel in patients with advanced cancer. Consequently, the hypothesis-generating NCI-ALMANAC web-based resource has demonstrated value in identifying promising combinations of approved drugs with potent anticancer activity for further mechanistic study and translation to clinical trials.",
author = "Holbeck, {Susan L.} and Richard Camalier and Crowell, {James A.} and Govindharajulu, {Jeevan Prasaad} and Melinda Hollingshead and Anderson, {Lawrence W.} and Eric Polley and Larry Rubinstein and Apurva Srivastava and Deborah Wilsker and Collins, {Jerry M.} and Doroshow, {James H.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1158/0008-5472.CAN-17-0489",
language = "English (US)",
volume = "77",
pages = "3564--3576",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - The National Cancer Institute ALMANAC

T2 - A comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity

AU - Holbeck, Susan L.

AU - Camalier, Richard

AU - Crowell, James A.

AU - Govindharajulu, Jeevan Prasaad

AU - Hollingshead, Melinda

AU - Anderson, Lawrence W.

AU - Polley, Eric

AU - Rubinstein, Larry

AU - Srivastava, Apurva

AU - Wilsker, Deborah

AU - Collins, Jerry M.

AU - Doroshow, James H.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - To date, over 100 small-molecule oncology drugs have been approved by the FDA. Because of the inherent heterogeneity of tumors, these small molecules are often administered in combination to prevent emergence of resistant cell subpopulations. Therefore, new combination strategies to overcome drug resistance in patients with advanced cancer are needed. In this study, we performed a systematic evaluation of the therapeutic activity of over 5,000 pairs of FDA-approved cancer drugs against a panel of 60 well-characterized human tumor cell lines (NCI-60) to uncover combinations with greater than additive growth-inhibitory activity. Screening results were compiled into a database, termed the NCI-ALMANAC (A Large Matrix of Anti-Neoplastic Agent Combinations), publicly available at https://dtp.cancer.gov/ncial manac. Subsequent in vivo experiments in mouse xenograft models of human cancer confirmed combinations with greater than single-agent efficacy. Concomitant detection of mechanistic biomarkers for these combinations in vivo supported the initiation of two phase I clinical trials at the NCI to evaluate clofarabine with bortezomib and nilotinib with paclitaxel in patients with advanced cancer. Consequently, the hypothesis-generating NCI-ALMANAC web-based resource has demonstrated value in identifying promising combinations of approved drugs with potent anticancer activity for further mechanistic study and translation to clinical trials.

AB - To date, over 100 small-molecule oncology drugs have been approved by the FDA. Because of the inherent heterogeneity of tumors, these small molecules are often administered in combination to prevent emergence of resistant cell subpopulations. Therefore, new combination strategies to overcome drug resistance in patients with advanced cancer are needed. In this study, we performed a systematic evaluation of the therapeutic activity of over 5,000 pairs of FDA-approved cancer drugs against a panel of 60 well-characterized human tumor cell lines (NCI-60) to uncover combinations with greater than additive growth-inhibitory activity. Screening results were compiled into a database, termed the NCI-ALMANAC (A Large Matrix of Anti-Neoplastic Agent Combinations), publicly available at https://dtp.cancer.gov/ncial manac. Subsequent in vivo experiments in mouse xenograft models of human cancer confirmed combinations with greater than single-agent efficacy. Concomitant detection of mechanistic biomarkers for these combinations in vivo supported the initiation of two phase I clinical trials at the NCI to evaluate clofarabine with bortezomib and nilotinib with paclitaxel in patients with advanced cancer. Consequently, the hypothesis-generating NCI-ALMANAC web-based resource has demonstrated value in identifying promising combinations of approved drugs with potent anticancer activity for further mechanistic study and translation to clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=85023780563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023780563&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-17-0489

DO - 10.1158/0008-5472.CAN-17-0489

M3 - Article

C2 - 28446463

AN - SCOPUS:85023780563

VL - 77

SP - 3564

EP - 3576

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 13

ER -